secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001104659-24-001556
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Phase 4 PIFR-2 study of YUPELRI fails to meet primary endpoint vs Spiriva HandiHaler in severe COPD
--------------------------------------------------------------------------------

- PIFR-2 study did not show statistically significant difference on primary endpoint (change in trough FEV1 at Day 85) for YUPELRI vs Spiriva HandiHaler.
- Both arms demonstrated similar lung function improvement; YUPELRI safety and tolerability consistent with prior studies.
- Study enrolled adults with severe to very severe COPD (FEV1 <50% predicted) and suboptimal PIFR (<55 L/min).
- CEO Rick E Winningham noted growth opportunities ahead for YUPELRI, an important COPD maintenance option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924001556/0001104659-24-001556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924001556/tm242154d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-001556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer